ArriVent BioPharma, Inc. - 8-K Filing

ArriVent BioPharma announced the publication of Phase 1b results for firmonertinib in Cancer Cell on October 19, 2026. (Items: 7.01 Regulation FD Disclosure)

SEC EDGAR · October 19, 2026, 12:09 UTC

Tickers: $AVBP

Read the full article at SEC EDGAR

Part of the story Strategy Inc - 8-K Filing (3 articles)

More Regulatory news

MiNK Therapeutics, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:49 UTC
SusGlobal Energy Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:42 UTC
Ideal Power Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:25 UTC
DIGI INTERNATIONAL INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:23 UTC
ZeroStack Corp. - 8-K Filing SEC EDGAR · November 12, 2026, 14:22 UTC
Sound Point Meridian Capital, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:22 UTC
Boost Run Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:20 UTC
INTERFACE INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:20 UTC
Neonode Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:20 UTC
Virtuix Holdings Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:20 UTC